{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ahlenstiel-Grunow T"],"funding":["Bundesministerium für Bildung und Forschung","Novartis"],"pagination":["502-516"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8054884"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["32(2)"],"pubmed_abstract":["Background
Pharmacokinetic monitoring is insufficient to estimate the intensity of immunosuppression after transplantation. Virus-specific T cells correlate with both virus-specific and general cellular immune defense. Additional steering of immunosuppressive therapy by virus-specific T cell levels might optimize dosing of immunosuppressants.Methods
In a multicenter, randomized, controlled trial, we randomized 64 pediatric kidney recipients to a control group with trough-level monitoring of immunosuppressants or to an intervention group with additional steering of immunosuppressive therapy by levels of virus-specific T cells (quantified by cytokine flow cytometry). Both groups received immunosuppression with cyclosporin A and everolimus in the same target range of trough le"],"journal":["Journal of the American Society of Nephrology : JASN"],"pubmed_title":["Steering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial."],"pmcid":["PMC8054884"],"funding_grant_id":["01EO0802"],"pubmed_authors":["Liu X","Großhennig A","Staude H","Sabau R","Oh J","Schild R","Taylan C","Weber LT","Pape L","Ahlenstiel-Grunow T","Verboom M","Schroder C"],"additional_accession":[]},"is_claimable":false,"name":"Steering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial.","description":"Background
Pharmacokinetic monitoring is insufficient to estimate the intensity of immunosuppression after transplantation. Virus-specific T cells correlate with both virus-specific and general cellular immune defense. Additional steering of immunosuppressive therapy by virus-specific T cell levels might optimize dosing of immunosuppressants.Methods
In a multicenter, randomized, controlled trial, we randomized 64 pediatric kidney recipients to a control group with trough-level monitoring of immunosuppressants or to an intervention group with additional steering of immunosuppressive therapy by levels of virus-specific T cells (quantified by cytokine flow cytometry). Both groups received immunosuppression with cyclosporin A and everolimus in the same target range of trough le","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Feb","modification":"2026-04-29T10:10:53.495Z","creation":"2022-02-11T15:44:01.696Z"},"accession":"S-EPMC8054884","cross_references":{"pubmed":["33323473"],"doi":["10.1681/asn.2020050645","10.1681/ASN.2020050645"]}}